Selzentry

The most common side effects occurring in greater than 8% of studied people include cough, pyrexia (fever), upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain, and dizziness. Other less common side effects may include allergic reactions, liver toxicity, and heart problems in people with a history of heart disease. Rarely, Selzentry can cause dizziness or fainting when standing up due to low blood pressure. Caution should be used when administering Selzentry in people with a history of or risk factors for postural hypotension, cardiovascular comorbidities, or taking concomitant medication known to lower blood pressure. Stop taking Selzentry and contact your provider right away if you develop a rash, yellowing of your eyes or skin, dark urine, vomiting, or upper stomach pain. Selzentry should not be used by people with severe or end-stage kidney disease who are taking medications that can affect the level of Selzentry (check with your provider). Selzentry affects immune system cells and could possibly increase the risk of infections and cancer, although this has not been observed in studies with up to five years of follow-up, and some data indicate it may be beneficial in cancer or for preventing metastasis (the spread of cancer to other parts of the body).

Dose adjustments with other medications and anti-HIV drugs include: 150 mg twice daily if taken with medications that increase levels of Selzentry, such as boosted protease inhibitors, Stribild, Genvoya, Tybost, clarithromycin, and itraconazole; 300 mg twice daily if taken with Viramune, Isentress, Tivicay, Triumeq, Fuzeon, and all of the NRTIs and medications that do not affect the levels of Selzentry; and 600 mg twice daily if taken with medications that decrease levels of Selzentry, such as Atripla, Sustiva, Intelence, rifampin, and some anti-convulsants such as carbamazepine (Tegretol), phenobarbital, and phenytoin (Dilantin). Likely dose with rifapentine is 600 mg twice daily, but use with caution. Not recommended with St. John’s wort. Selzentry may be co-administered with the hepatitis C medication Harvoni at a dose of 300 mg twice daily; however, ledipasvir (in Harvoni) may have potential to increase Selzentry levels. Tell your provider or pharmacist about all medications, herbals, and supplements you are taking or thinking of taking, prescribed or not, as there are other drug interactions which are not listed here.

Not recommended by DHHS as a component of an initial regimen due to requirement of CCR5 tropism testing prior to initiation of therapy, lack of virologic benefit when compared to other recommended regimens, and because it requires twice-daily dosing.

Selzentry is generally recommended only when HIV medications from other classes cannot be used or when a new class of medication is needed to construct a complete and durable treatment regimen for people who have drug resistance. Complex dosing, the need for a tropism test, and competition from newer drugs have dimmed some of the initial enthusiasm for this drug. In research bringing Trogarzo to market, Selzentry was often chosen to help create an optimized background regimen. Research participants had extensive HIV drug resistance. A tropism assay (Trofile, Trofile DNA, or HIV-1 Coreceptor Tropism with Reflex to UDS) is needed to determine if this medication will work. Results of a phenotypic tropism test (Trofile or Trofile DNA) may take up to a month to complete. Genotypic tests are also available and may provide a faster and less expensive alternative. Learn about Selzentry’s mechanism of action at youtube.com/watch?v=oneYI0fhGa0. Selzentry only works for people with CCR5-tropic virus. Viral tropism refers to the types of HIV that a person can have, CCR5 (R5), CXCR4 (X4), or Dual-Mix Tropic (R5 and X4). Selzentry blocks CCR5, a co-receptor on the outside of a CD4 cell, and shuts down this point of entry for the virus. Most people have acquired R5 virus initially, and then over time, X4 and mixed viruses may predominate. Blocking R5 with Selzentry does not cause a shift to X4 or negatively affect disease progression or CD4 count in people whose virus can use dual-mix. The tropism test needed is now generally paid for by public health departments, Medicare, and private insurance. ViiV may cover the payment for the Trofile test under certain circumstances.

Selzentry seems to have minimal impact on lipid levels. DHHS guidelines do not recommend the use of maraviroc for treatment-naïve individuals who are pregnant. Anyone who becomes pregnant while taking maraviroc may continue if viral suppression is effective and the regimen is well tolerated. The pharmacokinetics of maraviroc are not significantly altered during pregnancy and no dosage adjustment is necessary. Maraviroc is known to have a moderate level of transfer across the human placenta, although insufficient data exist to evaluate the effects on a fetus. Pregnant individuals can voluntarily enroll in the Antiretroviral Pregnancy Registry through their provider; go to apregistry.com.

Dr. Melanie Thompson:

The only approved CCR5 entry inhibitor, maraviroc is not for initial therapy. It may be helpful, however, for people who have substantial viral resistance and struggle to put together a viable regimen. Selzentry only works against HIV that uses the CCR5 receptor, requiring a viral tropism test before using the drug. The drug requires twice-daily dosing, making adherence more challenging, and it has many drug-drug interactions requiring dose adjustments of Selzentry or the other drug. Selzentry 25 mg and 75 mg tablets will be discontinued as of January 1, 2024.

The monthly wholesale acquisition cost of Selzentry 300 mg is $1,633.

Activist Joey Wynn:

Selzentry, or maraviroc, is a CCR5 antagonist. Selzentry is for use only in highly treatment-experienced people, with many past failed regimens. Selzentry is one pill, twice daily, with or without food. Given other available options, I don’t believe anyone would want to choose Selzentry, even those who are highly treatment-experienced and have limited treatment options.